Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 5,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Terminated Phase 1 Interventional

Study of LM-102 in Subjects in Advanced Tumors

NCT04735796
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Drug：LM-102
Drug
Lead sponsor
LaNova Medicines Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
California City, California • Indianapolis, Indiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Phase 1 Interventional

A Study of EBC-129 in Advanced Solid Tumours

NCT05701527
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
EBC-129, Pembrolizumab
Drug
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Government
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 1Phase 2 Interventional

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

NCT01009242
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis
Interventions
CDP6038, Placebo IV, Placebo SC, CDP 6038 SC, Methotrexate
Biological · Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 23, 2026, 2:51 AM EDT
Suspended Phase 1Phase 2 Interventional

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

NCT03208296
View directory record Official record
Conditions
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Interventions
ASN-002
Biological
Lead sponsor
Ascend Biopharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies

NCT05548413
View directory record Official record
Conditions
Medication Adherence, Heart Failure
Interventions
FamLit, Attention Control
Behavioral
Lead sponsor
Jia-Rong Wu
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603
View directory record Official record
Conditions
Lichen Planopilaris
Interventions
Oral Brepocitinib, Placebo
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Games to Help Canadian and U.S. Adults Identify COVID-19 and Vaccine Misinformation: Three Sequential Randomized Studies

NCT07758309
View directory record Official record
Conditions
COVID-19, Vaccine Hesitancy, Health Misinformation, Communication
Interventions
Gamified misinformation refutation quiz, Refutational text (active control)
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
3,637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02760264
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone 0.25 mg/kg/day, Vamorolone 0.75 mg/kg/day, Vamorolone 2.0 mg/kg/day, Vamorolone 6.0 mg/kg/day
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
4 Years to 6 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional

Improving Medication Adherence in Pediatric Inflammatory Bowel Disease

NCT01536509
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Disease
Interventions
Telehealth Behavioral Treatment (TBT), Education Only (EO)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
San Francisco, California • Hartford, Connecticut • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional Results available

Single-arm Phase II Study of NDURE for Patients With HNC

NCT03821064
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Patient Navigation
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Empowering Cessation ACS South Region

NCT06820034
View directory record Official record
Conditions
Smoking Cessation
Interventions
Empowering Cessation for the ACS South
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Epileptic Hippocampus in Alzheimer's Disease

NCT05899764
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Brivaracetam
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional

A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery

NCT03115398
View directory record Official record
Conditions
Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer, Cervical Cancer
Interventions
Pedometer-based Walking Program
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

NCT00761657
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
34
States / cities
Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 23, 2026, 2:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

NCT07011667
View directory record Official record
Conditions
Obesity
Interventions
CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
47
States / cities
Costa Mesa, California • San Diego, California • Walnut Creek, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Terminated Phase 1 Interventional

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

NCT00074607
View directory record Official record
Conditions
Meningitis, Neoplasms
Interventions
Gemcitabine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
5
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Phase 1 Interventional

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

NCT06795009
View directory record Official record
Conditions
Uterine Cancer, Endometrial Cancer
Interventions
Zanzalintinib, Paclitaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
4
States / cities
San Francisco, California • St Louis, Missouri • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed No phase listed Observational

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

NCT00516698
View directory record Official record
Conditions
Breast Cancer
Interventions
polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography
Genetic · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
180
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 23, 2026, 2:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

NCT00889187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Neoadjuvant Short-Course Photon Radiation, Capecitabine
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 23, 2026, 2:51 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined, Intravesical NAI (Cohorts 6-7), Subcutaneous NAI (Cohort 8)
Drug · Radiation · Biological + 1 more
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional

12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN

NCT03511755
View directory record Official record
Conditions
Psoriasis, Stress
Interventions
Transdermal Electrical Neuromodulator (TEN)
Device
Lead sponsor
Thync Global, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Fremont, California • San Diego, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Make Better Choices

NCT01249989
View directory record Official record
Conditions
Health Behavior
Interventions
Sequential MBC Condition, Simultaneous MBC Condition, Stress Management
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 23, 2026, 2:51 AM EDT
Not yet recruiting Not applicable Interventional

Effects of a Mobile App-Based Mindfulness Intervention in Persons With Spinal Cord Injury and Chronic Pain

NCT06891989
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Mindfulness meditation (MM) Intervention, Health Education Active Control Intervention
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Not applicable Interventional

Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease

NCT07090668
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
tAN device
Device
Lead sponsor
Emory University
Other
Eligibility
7 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 2:51 AM EDT